Abstract
Lung malignancy is a leading cause of cancer related morbidity and mortality worldwide. The majority (85%) of cases are histologically proven non-small cell lung carcinomas (NSCLC). More than 55% of lung carcinomas harbor at least one genetic alteration, most of them being histologic subtype specific. This review summarizes the progress in personalized care of lung cancer by reviewing the literature on EGFR, ALK and KRAS molecular alterations, currently used in clinical practice, to direct the decision making process for lung cancer therapy. In addition, we will discuss some recently characterized molecular alterations whose targeting is being tested in clinical trials and holds promise for future therapeutic targeting. The role of minimally invasive procedures in lung cancer diagnosis and staging is also discussed as these techniques now play a central role in lung cancer management by providing the bulk of material for modern molecular diagnostics.
Current Molecular Pharmacology
Title:Molecular Testing and Personalized Treatment of Lung Cancer
Volume: 7
Author(s): Fotis Sampsonas, Daniel Ryan, Dympna McPhillips and David P. Breen
Affiliation:
Keywords: ALK/FISH, EGFR, EBUS, KRAS, lung cancer, NSCLC.
Abstract: Lung malignancy is a leading cause of cancer related morbidity and mortality worldwide. The majority (85%) of cases are histologically proven non-small cell lung carcinomas (NSCLC). More than 55% of lung carcinomas harbor at least one genetic alteration, most of them being histologic subtype specific. This review summarizes the progress in personalized care of lung cancer by reviewing the literature on EGFR, ALK and KRAS molecular alterations, currently used in clinical practice, to direct the decision making process for lung cancer therapy. In addition, we will discuss some recently characterized molecular alterations whose targeting is being tested in clinical trials and holds promise for future therapeutic targeting. The role of minimally invasive procedures in lung cancer diagnosis and staging is also discussed as these techniques now play a central role in lung cancer management by providing the bulk of material for modern molecular diagnostics.
Export Options
About this article
Cite this article as:
Sampsonas Fotis, Ryan Daniel, McPhillips Dympna and Breen P. David, Molecular Testing and Personalized Treatment of Lung Cancer, Current Molecular Pharmacology 2014; 7 (1) . https://dx.doi.org/10.2174/187446720701150105171219
DOI https://dx.doi.org/10.2174/187446720701150105171219 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PreQ<sub>0</sub> Base, an Unusual Metabolite with Anti-cancer Activity from Streptomyces qinglanensis 172205
Anti-Cancer Agents in Medicinal Chemistry Intracellular Disposition of Methotrexate in Acute Lymphoblastic Leukemia in Children
Current Drug Metabolism Advances in Hyaluronic Acid-Based Drug Delivery Systems
Current Drug Targets Myeloma Cells and Their Interactions With the Bone Marrow Endothelial Cells
Current Immunology Reviews (Discontinued) Combination Treatment of p53-Null HL-60 cells with Histone Deacetylase Inhibitors and Chlorambucil Augments Apoptosis and Increases BCL6 and p21 Gene Expression
Current Molecular Pharmacology Composite Lymphomas: A Challenging Entity
Current Cancer Therapy Reviews Effect of Recombinant Human Thymosin-α1, an Immuno-Modulating Peptide with 28 Amino Acids, on the Activity of Cytochrome P450s
Drug Metabolism Letters Amino Acid Derived Prodrugs: An Approach to Improve the Bioavailability of Clinically Approved Drugs
Current Topics in Medicinal Chemistry Synthesis and Anticancer Activity of Some 1H-inden-1-one Substituted (Heteroaryl)Acetamide Derivatives
Letters in Drug Design & Discovery Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner
Current Drug Metabolism Cytotoxic Nucleoside Analogues: Different Strategies to Improve their Clinical Efficacy
Current Medicinal Chemistry Antioxidant Effect of a Nitrated Cyclic Nucleotide Functioning as an Endogenous Electrophile
Current Topics in Medicinal Chemistry Drug Discovery by Targeting Mutant KRAS
Current Topics in Medicinal Chemistry Effect of Particle Formulation on Dry Powder Inhalation Efficiency
Current Pharmaceutical Design Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge
Current Cancer Drug Targets Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway
Anti-Cancer Agents in Medicinal Chemistry Formulations, Pharmacodynamic and Clinical Studies of Nanoparticles for Lung Cancer Therapy - An Overview
Current Drug Metabolism The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design Recent Advances in Multinuclear Complexes as Potential Anticancer and DNA Binding Agents
Anti-Cancer Agents in Medicinal Chemistry Radiotracers in Oncology
Current Radiopharmaceuticals